| Name | Title | Contact Details |
|---|
Developing high-value, global products for patients with significant unmet medical needs in niche indications
Greater Nashua Mental Health believes in empowering people to lead full and satisfying lives through effective treatment and support.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Abbott is a global healthcare company that conducts innovative research and manufactures products for human health through every life stage. They bring new products and technologies to the world in nutrition, diagnostics, medical devices and branded ge...
Oread is a Lawrence, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.